Cambridge Trust’s Akero Therapeutics AKRO Stock Holding History

Cambridge Trust’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$88.4K	Hold	3,500	–	–	﹤0.01%	360
2023 Q4	$81.7K	Hold	3,500	–	–	﹤0.01%	365
2023 Q3	$177K	Hold	3,500	–	–	0.01%	271
2023 Q2	$163K	Hold	3,500	–	–	0.01%	290
2023 Q1	$134K	Hold	3,500	–	–	0.01%	323
2022 Q4	$192K	Hold	3,500	–	–	0.01%	293
2022 Q3	$119K	Hold	3,500	–	–	0.01%	338
2022 Q2	$33K	Hold	3,500	–	–	﹤0.01%	543
2022 Q1	$50K	Hold	3,500	–	–	﹤0.01%	528
2021 Q4	$74K	Buy	+3,500	New	+$77.6K	﹤0.01%	470

Other funds holding AKRO

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Cambridge Trust's AKRO Position: Q1 2024 in Review

Cambridge Trust held its Akero Therapeutics (AKRO) position steady in Q1 2024 at 3,500 shares worth $88.4K. The position accounts for ﹤0.01% of the portfolio, ranked #360.

Cambridge Trust first reported a position in AKRO in Q4 2021 and has held it in 10 quarters since. The position peaked at $192K in Q4 2022. 173 funds tracked by Wall St. Rank hold AKRO as of Q1 2024.

Cambridge Trust held 3,500 shares of Akero Therapeutics worth $88.4K as of Q1 2024.
Cambridge Trust left its Akero Therapeutics share count unchanged in Q1 2024.
Akero Therapeutics made up ﹤0.01% of Cambridge Trust's portfolio in Q1 2024, its #360 holding.
Cambridge Trust first reported a position in Akero Therapeutics in Q4 2021 and has held it in 10 quarters since.
Cambridge Trust's Akero Therapeutics position peaked at $192K in Q4 2022.
173 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.